Nandrolone Decanoate

—

evidence score

anabolic

Prescription Only

Deca-DurabolinDecanandrolone+2 more

Nandrolone Decanoate (Deca-Durabolin) is one of the most widely prescribed anabolic steroids medically, FDA-approved for anemia (increases EPO and erythropoiesis), breast cancer, and osteoporosis. It is a 19-nortestosterone derivative with a favorable side effect profile compared to testosterone in several respects — lower DHT conversion (converts to weak dihydronandrolone), lower androgenic side effects, less hair loss. However, it has significant progestogenic activity and causes "Deca dick" (erectile dysfunction) via dopaminergic suppression if not combined with adequate testosterone. Famous for joint lubrication effects (increased synovial fluid and collagen synthesis). Long half-life (6-12 days) requires patience with dosing.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

400 mg

200 mgRange600 mg

Frequencyweekly or twice weekly

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~6-12 days

OnsetJoint relief 2-4 weeks; anabolic effects 4-8 weeks; full effects 12+ weeks

DurationVery long-acting; detectable on drug tests up to 18+ months

Routes

intramuscular_injection

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Nandrolone Decanoate is currently categorized as a anabolic compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

AR agonist with lower DHT conversion; progestogen receptor agonism; increases collagen synthesis (II and III); stimulates EPO; IGF-1 upregulation; glucocorticoid antagonism

Practical Context

Strongest current signals

No indexed study summaries yet.

Elevated caution signals

2 severe/high side effect flags